Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Next Previous
Trial Profile

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-0466 (Primary)
  • Indications Acute myeloid leukaemia; Adrenal cancer; Anal cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Haematological malignancies; Lung cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma; Small cell lung cancer; Solid tumours; Tumour lysis syndrome; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 20 Apr 2023 According to Starpharma media release, clinical trial data from this trial presented in a poster presentation by AstraZeneca at the AACR Annual Meeting.
    • 22 Mar 2023 According to Starpharma media release, company will present the new data of this study at the upcoming American Association for Cancer Research Annual Meeting in April 2023.
    • 22 Apr 2022 Status changed from completed to discontinued.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top